BR112014021959A8 - Composição de vacina de salmonella para aves - Google Patents

Composição de vacina de salmonella para aves

Info

Publication number
BR112014021959A8
BR112014021959A8 BR112014021959A BR112014021959A BR112014021959A8 BR 112014021959 A8 BR112014021959 A8 BR 112014021959A8 BR 112014021959 A BR112014021959 A BR 112014021959A BR 112014021959 A BR112014021959 A BR 112014021959A BR 112014021959 A8 BR112014021959 A8 BR 112014021959A8
Authority
BR
Brazil
Prior art keywords
vaccine
vaccine composition
antigen
poultry
gram
Prior art date
Application number
BR112014021959A
Other languages
English (en)
Other versions
BR112014021959A2 (pt
BR112014021959B1 (pt
Inventor
Sakamoto Ryuichi
Sakaguchi Masashi
Original Assignee
The Chemo Sero Therapeutic Res Institute
Km Biologics Co Ltd
Meiji Animal Health Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Chemo Sero Therapeutic Res Institute, Km Biologics Co Ltd, Meiji Animal Health Co Ltd filed Critical The Chemo Sero Therapeutic Res Institute
Publication of BR112014021959A2 publication Critical patent/BR112014021959A2/pt
Publication of BR112014021959A8 publication Critical patent/BR112014021959A8/pt
Publication of BR112014021959B1 publication Critical patent/BR112014021959B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/235—Adenoviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
    • C12N2710/10271—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20071—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

VACINA LPS. A presente invenção refere-se a uma composição de vacina para aves, a qual contém uma estrutura que contém um O-antígeno originado de uma bactéria Gram-negativa (em que uma célula integral não é incluída dentro do âmbito da estrutura) como ingrediente ativo; e um método para a produção da composição de vacina. Na presente invenção, uma estrutura contendo um O-antígeno iriginado de uma bactéria Gram-negativa (por exemplo, um lipopolissacarídeo) é usada como um antígeno para a vacina. Portanto, a ocorrência de uma reação de vacinação pode ser reduzida e a quantidade de uma solução de injeção também pode ser reduzida em comparação com aquelas em vacinas de células integrais convencionais, e uma vacina multimista pode ser preparada.
BR112014021959-1A 2012-03-22 2013-02-19 Composição de vacina de salmonella para aves BR112014021959B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012065162 2012-03-22
JP2012-065162 2012-03-22
PCT/JP2013/054038 WO2013140919A1 (ja) 2012-03-22 2013-02-19 Ｌｐｓワクチン

Publications (3)

Publication Number Publication Date
BR112014021959A2 BR112014021959A2 (pt) 2017-06-20
BR112014021959A8 true BR112014021959A8 (pt) 2022-10-18
BR112014021959B1 BR112014021959B1 (pt) 2022-12-06

Family

ID=49222384

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014021959-1A BR112014021959B1 (pt) 2012-03-22 2013-02-19 Composição de vacina de salmonella para aves

Country Status (9)

Country Link
US (3) US9345756B2 (pt)
EP (1) EP2829281B1 (pt)
JP (1) JP6088489B2 (pt)
CN (1) CN104244972A (pt)
BR (1) BR112014021959B1 (pt)
ES (1) ES2708430T3 (pt)
MX (1) MX362955B (pt)
RU (1) RU2637448C2 (pt)
WO (1) WO2013140919A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013140919A1 (ja) * 2012-03-22 2013-09-26 一般財団法人化学及血清療法研究所 Ｌｐｓワクチン
RU2016109366A (ru) * 2013-10-03 2017-11-10 Нитто Денко Корпорейшн Назальная мукозальная вакцинная композиция
CN106177937A (zh) * 2016-07-25 2016-12-07 江苏省农业科学院 鸡减蛋综合征和禽脑脊髓炎二联灭活疫苗及其制备方法
CN109486741B (zh) * 2018-12-20 2021-10-29 天津瑞普生物技术股份有限公司 一种副鸡禽杆菌的灭活方法
IL293167A (en) * 2019-11-29 2022-07-01 Boehringer Ingelheim Vetmedica Gmbh Triple vaccine against Avibacterium paraglinarum, fowl pox virus and fowl pox virus
US20220053799A1 (en) * 2020-06-26 2022-02-24 Zivo Bioscience, Inc. Positive latency effects on coccidiosis prevention and treatment via animal feed
EP4171623A4 (en) * 2020-06-26 2024-08-14 Zivo Bioscience Inc EFFECTS OF POSITIVE LATENCY ON PREVENTION AND TREATMENT OF COCCIDIOSIS THROUGH ANIMAL FEED
MX2023001775A (es) * 2020-08-12 2023-03-10 Zivo Bioscience Inc El uso de microbios variovorax como un tratamiento alternativo para la coccidiosis.
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713073B1 (en) 1998-07-24 2004-03-30 Megan Health, Inc. Method of vaccination of newly hatched poultry
JP4456698B2 (ja) 1999-07-16 2010-04-28 生化学工業株式会社 エンドトキシンショック抑制剤
WO2004052394A1 (en) 2002-12-06 2004-06-24 Biosynth S.R.L. Broad-spectrum lps based vaccines of unencapsulated strains of haemophilus influenzae and other pathogenic species of gram-negative bacteria
CA2565247C (en) * 2004-05-14 2014-03-25 National Research Council Canada Conserved inner core lipopolysaccharide epitopes as multi-species vaccine candidates
US20050260225A1 (en) 2004-05-18 2005-11-24 Goldberg Joanna B Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
UA100370C2 (uk) 2006-12-11 2012-12-25 Мериал Лимитед Спосіб вакцинації птахів проти salmonella
US8465755B2 (en) * 2007-10-05 2013-06-18 The Arizona Board Of Regents For And On Behalf Of Arizona State University Recombinant bacterium capable of eliciting an immune response against enteric pathogens
RU2377015C1 (ru) * 2008-04-29 2009-12-27 Николай Васильевич Пименов Вакцина инактивированная против сальмонеллеза голубей и способ ее применения
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
WO2013140919A1 (ja) * 2012-03-22 2013-09-26 一般財団法人化学及血清療法研究所 Ｌｐｓワクチン

Also Published As

Publication number Publication date
CN104244972A (zh) 2014-12-24
EP2829281A1 (en) 2015-01-28
RU2637448C2 (ru) 2017-12-04
MX362955B (es) 2019-02-26
ES2708430T3 (es) 2019-04-09
US20150086590A1 (en) 2015-03-26
US20160228526A1 (en) 2016-08-11
EP2829281B1 (en) 2019-01-16
MX2014011305A (es) 2014-10-17
BR112014021959A2 (pt) 2017-06-20
JPWO2013140919A1 (ja) 2015-08-03
BR112014021959B1 (pt) 2022-12-06
US10279025B2 (en) 2019-05-07
US9345756B2 (en) 2016-05-24
US20170281745A1 (en) 2017-10-05
EP2829281A4 (en) 2015-11-11
JP6088489B2 (ja) 2017-03-01
RU2014138021A (ru) 2016-05-20
WO2013140919A1 (ja) 2013-09-26

Similar Documents

Publication Publication Date Title
BR112014021959A8 (pt) Composição de vacina de salmonella para aves
BR112017001310A2 (pt) coronavírus
BR112013022397A2 (pt) vacinas combinadas com doses menores de antígeno e/ou adjuvante
TR201908003T4 (tr) TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları.
PE20142291A1 (es) Composiciones nutricionales a base de fitonutrientes
BR112018075162A2 (pt) composições para higiene bucal
BR112016013493A2 (pt) molécula de ácido nucleico, composição, vacina, e, métodos para prevenção de uma doença em um indivíduo com necessidade da mesma e para tratamento de uma doença em um indivíduo com necessidade do mesmo
BR112014013276A2 (pt) vetores hvt recombinantes expressando antígenos de patógenos aviários e usos dos mesmos
BR112018011216A2 (pt) métodos para inibir a conversão de colina em trimetilamina (tma)
GT201400210A (es) Vacuna contra mycoplasma hyopneumoniae
BR112014011334A2 (pt) inicialização de contexto baseada em memória temporária de amortecimento
BR112016006945A2 (pt) métodos e aparelhos para sincronização de tempo e frequência assistida por equipamento de usuário de pequenas células
BR112015023507A2 (pt) vacina estável líquida, e, métodos para vacinar um bovino e para produzir uma vacina estável líquida
BR112013029677A2 (pt) estirpes de salmonella gallinarum avirulentas modificadas e composições farmacêuticas que utilizam as mesmas
BR112016007182A2 (pt) método para produzir um l-aminoácido
BR102014009838B8 (pt) Método para produzir um l-aminoácido
CL2013003144A1 (es) Composicion que comprende a) extracto de arroz fermentado con monascus purpureus, b) un acido graso omega, c) l-carnitina y uno o mas de los siguientes: d) al menos un policosanol, e) resveratrol, f) coenzima q10 y g) al menos una vitamina, util como anticolesterolemico y antitrigliceridemico y para aumentar el colesterol hdl.
BR112017008033A2 (pt) composição farmacêutica para administração oral e respectivo processo de preparação
BR112015013349A2 (pt) trieptanoína para o tratamento de deficiência de transportador de glicose 1
BR112013026661A2 (pt) método de entrega de vacina
BR112014012306A2 (pt) soluções de colina estabilizadas e métodos para preparar as mesmas
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112018013292A2 (pt) ?método para preparar uma preparação de e. hallii e para promover formação de ácido butírico, e, preparação de e. hallii?
BR112016026651A2 (pt) evolução de vesículas semelhantes a vírus de alta titulação para aplicações de vacina
BR112016030294A8 (pt) cepa de bactérias probióticas de lactobacillus e uma vacina de aves domésticas, composição, ovo de aves domésticas embrionado, kit, e, método de vacinação in ovo de aves domésticas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25G Requested change of headquarter approved

Owner name: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE (JP)

B25A Requested transfer of rights approved

Owner name: KM BIOLOGICS CO., LTD. (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: MEIJI ANIMAL HEALTH CO., LTD. (JP)

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/02/2013, OBSERVADAS AS CONDICOES LEGAIS